Financial reports

KARO PHARMA TRIPLES SALES AND PROFIT IN THE SECOND QUARTER

19 July, 2018

INTERIM REPORT JANUARY – JUNE 2018   THE PERIOD AND THE SECOND QUARTER · Net sales amounted to MSEK 756.5 (281.8), of which the second quarterly MSEK 489.4 (142.5). This corresponds to an increase of 168.5%, and for the second quarter of 243.5%. Growth was driven mainly by acquisitions. · Organic growth during the period...

Läs mer

ANNUAL REPORT 2017

16 May, 2018

Läs mer

KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

26 April, 2018

INTERIM REPORT JANUARY – MARCH 2018 · Net sales amounted to MSEK 267.1 (139.3), equivalent to an increase of 91.7%. Growth was mainly due to acquisitions. · Organic growth was +10.7%, whereof pharmaceuticals +18.8% and other products +4% · The gross margin was 56.8% (53.7%) for the period. · EBITDA amounted to MSEK 88.7 (43.7),...

Läs mer

YEAR-END REPORT 2017

22 February, 2018

THE FULL YEAR AND FOURTH QUARTER · Net sales amounted to MSEK 657.6 (347.3), whereof the fourth quarter MSEK 238.7 (96.5), representing an increase of 89 percent for the year and 147 percent for the quarter. · Adjusted EBITDA amounted to MSEK 169.3 (51.7), whereof the fourth quarter MSEK 41.8 (28.9) representing a margin of...

Läs mer